Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) - HC Wainwright dropped their FY2026 earnings per share (EPS) estimates for Kyverna Therapeutics in a note issued to investors on Friday, November 13th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings of ($2.71) per share for the year, down from their prior forecast of ($2.70). HC Wainwright has a "Buy" rating on the stock. The consensus estimate for Kyverna Therapeutics' current full-year earnings is ($2.70) per share. HC Wainwright also issued estimates for Kyverna Therapeutics' Q4 2027 earnings at ($0.53) EPS and FY2027 earnings at ($2.78) EPS.
Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.01.
Other equities analysts have also recently issued reports about the stock. William Blair upgraded shares of Kyverna Therapeutics to a "strong-buy" rating in a research report on Wednesday, September 23rd. Benchmark reissued a "buy" rating on shares of Kyverna Therapeutics in a research note on Friday, September 25th. Weiss Ratings restated a "sell (d-)" rating on shares of Kyverna Therapeutics in a research report on Monday, September 21st. Finally, Needham & Company LLC set a $25.00 target price on shares of Kyverna Therapeutics in a research note on Friday, September 25th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Kyverna Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $29.00.
Check Out Our Latest Report on Kyverna Therapeutics
Kyverna Therapeutics Price Performance
KYTX opened at $4.76 on Tuesday. The company's 50 day moving average is $6.15 and its 200-day moving average is $7.86. Kyverna Therapeutics has a 1-year low of $4.49 and a 1-year high of $13.67. The company has a debt-to-equity ratio of 0.15, a quick ratio of 9.06 and a current ratio of 9.06.
Institutional Trading of Kyverna Therapeutics
Hedge funds have recently made changes to their positions in the company. Aquatic Capital Management LLC bought a new stake in shares of Kyverna Therapeutics during the third quarter worth about $488,000. Goldman Sachs Group Inc. raised its holdings in Kyverna Therapeutics by 64.6% in the 3rd quarter. Goldman Sachs Group Inc. now owns 551,899 shares of the company's stock valued at $3,753,000 after buying an additional 216,669 shares during the last quarter. Marshall Wace LLP bought a new position in Kyverna Therapeutics in the 3rd quarter valued at approximately $498,000. Empowered Funds LLC acquired a new stake in Kyverna Therapeutics during the 3rd quarter worth approximately $127,000. Finally, Kovack Advisors Inc. acquired a new stake in Kyverna Therapeutics during the 3rd quarter worth approximately $65,000. 18.08% of the stock is owned by institutional investors and hedge funds.
About Kyverna Therapeutics
(
Get Free Report)
Kyverna Therapeutics is a clinical-stage biopharmaceutical company developing cell therapies for people with autoimmune diseases. The company's approach aims to use engineered immune cells to address disease-causing B cells. Its lead candidate, KYV-101, is an autologous CAR T-cell therapy designed to target CD19, a protein found on B cells. Kyverna is evaluating the therapy in clinical studies for several autoimmune conditions, including stiff person syndrome, myasthenia gravis and lupus nephritis.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Kyverna Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kyverna Therapeutics wasn't on the list.
While Kyverna Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.